Labcorp Venture Fund, Mayo Clinic, Sutter Health, InterVest, MGFO,

Labcorp风险基金，梅奥诊所，萨特健康，InterVest，MGFO，

PGGM,

PGGM，

Puma Venture Capital,

彪马风险资本，

and ROM Utrecht

和乌得勒支ROM博物馆

invest alongside existing investors Invest-NL, EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital

与现有投资者Invest-NL、EIC基金、Fred Moll、NYBC Ventures和Sonder Capital一起投资

UTRECHT, Netherlands

荷兰乌得勒支

,

，

March 10, 2026

2026年3月10日

/PRNewswire/ -- Vitestro, the pioneer in medical robotics advancing automated diagnostic blood collection, today announced the close of a $70 million oversubscribed Series B financing.

/PRNewswire/ -- Vitestro，医疗机器人领域的先锋，致力于推进自动化诊断性采血技术，今日宣布完成了7000万美元超额认购的B轮融资。

The round includes new strategic investment from U.S. healthcare leaders Labcorp Venture Fund, Mayo Clinic, and Sutter Health, new financial investors

本轮融资包括来自美国医疗保健领域领导者Labcorp风险基金、梅奥诊所和Sutter Health的新战略投资，以及新的财务投资者。

InterVest, MGFO,

InterVest，MGFO，

PGGM,

PGGM，

Puma Venture Capital,

彪马风险资本，

and ROM Utrecht, and continued support from existing investors

并得到了ROM乌得勒支的参与，以及现有投资者的持续支持

Invest-NL (supported by InvestEU), EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital.

荷兰投资局（由InvestEU支持）、欧洲创新委员会基金、弗雷德·莫尔、纽约血液中心风险投资公司和声纳资本。

Continue Reading

继续阅读

Toon Overbeeke with Aletta®, Vitestro’s device for autonomous blood draws

图恩·奥弗贝克与Aletta®，Vitestro的自主抽血设备

Proceeds will be used to advance the next generation Aletta

所得款项将用于推进下一代Aletta的发展

®

®

Autonomous Robotic Phlebotomy Device™ (ARPD™), enabling deeper integration into high-volume clinical workflows. The funding will also support Vitestro's U.S. FDA De Novo regulatory pathway and global commercial readiness, including manufacturing scale-up, clinical expansion, and commercial infrastructure development, as the company prepares for broader market adoption beginning in Europe and progressing toward the U.S.

自主机器人静脉采血设备™（ARPD™），能够更深入地融入高通量临床工作流程。这笔资金还将支持Vitestro的美国FDA De Novo监管路径及全球商业化准备，包括制造规模扩大、临床扩展以及商业基础设施开发，因为该公司正准备从欧洲开始推广市场，并逐步迈向美国。

market..

市场。。

'Closing our Series B financing reflects strong conviction in our mission to establish a new standard in autonomous robotic venous access and diagnostic blood collection,' said Toon Overbeeke, Chief Executive Officer and co-founder of Vitestro. 'Our technology has evolved from a novel vision into a clinically validated reality, and we are grateful for the support of this distinguished syndicate of strategic, healthcare, and life science investors as we move toward broad clinical adoption.

“完成我们的B轮融资反映了各方对我们建立自动机器人静脉通路和诊断性血液采集新标准使命的强烈信心，”Vitestro首席执行官兼联合创始人图恩·奥弗比克表示。“我们的技术已经从一个新颖的愿景发展为经过临床验证的现实，我们非常感谢这一卓越的战略、医疗和生命科学投资者团队的支持，因为我们正朝着广泛的临床应用迈进。”

Diagnostic blood collection remains the highest-volume invasive medical procedure globally, with billions of procedures performed annually.'.

诊断性采血仍然是全球最高频次的侵入性医疗操作，每年进行数十亿次。

Vitestro leadership will use the proceeds to further advance the platform's technical capabilities and integration into existing technology infrastructure, conduct essential clinical studies and pilot programs to embed the technology into real-world workflows, and expand its team to meet growing demand from healthcare providers..

Vitestro的领导层将利用这笔资金进一步提升平台的技术能力并将其整合到现有的技术基础设施中，开展必要的临床研究和试点项目以将该技术融入实际工作流程，并扩大团队以满足医疗保健提供者不断增长的需求。

'The Labcorp Venture Fund sees strong potential in solutions that modernize core diagnostic processes and improve consistency for patients,' said Megann Vaughn Watters, Head of Labcorp Venture Fund. 'Applying robotics, multimodal imaging and AI to clinically validated diagnostic blood collection is an exciting approach, and we're thrilled to support Vitestro as they advance this important work.'.

“Labcorp风险基金看到现代化核心诊断流程并提高患者一致性的解决方案的巨大潜力，” Labcorp风险基金负责人Megann Vaughn Watters表示。“将机器人技术、多模态成像和人工智能应用于临床验证的诊断性采血是一种令人兴奋的方法，我们非常高兴支持Vitestro推进这项重要工作。”

'Vitestro is redefining one of the largest and most under innovated clinical workflows with a first-of-its-kind autonomous robotic platform for diagnostic blood collection addressing an enormous unmet global market need,' said Dr. Fred Moll, co-founder and partner at Sonder Capital and former co-founder and CEO of Intuitive Surgical and Auris Health.

“Vitestro正在通过一种首创的自主机器人平台重新定义最大且最缺乏创新的临床工作流程之一，该平台用于诊断性采血，满足了全球范围内巨大的未满足市场需求，”Sonder Capital的联合创始人兼合伙人、Intuitive Surgical和Auris Health的前联合创始人兼首席执行官Fred Moll博士表示。

'I believe this technology has the potential to establish a new standard of care, much as robotic surgery did in its early days.'.

“我相信这项技术有潜力确立一种新的护理标准，就像机器人手术在早期所做的那样。”

The Aletta

阿莱塔号

®

®

ARPD™ is designed to autonomously perform diagnostic blood collection. The system combines multimodal imaging, advanced robotics, and artificial intelligence to identify suitable veins, guide needle insertion, and collect blood samples with high precision and consistency. Aletta

ARPD™ 旨在自主执行诊断性血液采集。该系统结合了多模态成像、先进机器人技术和人工智能，以识别合适的静脉、引导针头插入并高精度且一致地收集血液样本。

®

®

is intended to support phlebotomy departments by performing routine diagnostic blood draws, helping address staffing challenges, reduce human-dependent variability, standardize quality, enhance the overall patient experience, and enable greater operational predictability and scalability in high-volume outpatient care settings..

旨在通过执行常规的诊断性抽血来支持静脉采血部门，帮助应对人员配置挑战，减少人为依赖的变异性，标准化质量，提升整体患者体验，并在高流量门诊护理环境中实现更高的运营可预测性和可扩展性。

For more information, visit

更多信息，请访问

www.vitestro.com

www.vitestro.com

About Vitestro

关于Vitestro

Vitestro is a global leader in medical robotics advancing diagnostic blood collection through autonomous technology. Headquartered in the Netherlands, the company brings deep expertise in engineering, robotics, artificial intelligence, and commercialization. Vitestro has developed Aletta

Vitestro 是一家全球领先的医疗机器人公司，通过自主技术推动诊断性采血的发展。公司总部位于荷兰，在工程、机器人、人工智能和商业化方面拥有深厚的专业知识。Vitestro 开发了 Aletta。

®

®

, the world's first and only CE-marked Autonomous Robotic Phlebotomy Device™ (ARPD™), establishing a new category and benchmark for diagnostic blood collection. By integrating advanced robotics, multimodal imaging, and AI, Vitestro is enabling greater precision, operational efficiency, and an improved patient experience in clinical settings.

，这是全球首个也是唯一一个获得CE认证的自主机器人静脉采血设备™（ARPD™），为诊断性血液采集设立了新的类别和基准。通过整合先进的机器人技术、多模态成像和人工智能，Vitestro正在临床环境中实现更高的精确性、操作效率，并改善患者的体验。

Aletta.

阿莱塔。

®

®

is currently CE-marked and is currently being deployed in clinical and pre-commercial settings in Europe and has not yet received FDA authorization in the U.S. Vitestro is actively advancing its U.S. regulatory pathway while expanding global clinical collaborations to support the future commercialization of autonomous diagnostic blood collection worldwide..

目前已获得CE认证，正在欧洲的临床和预商业环境中部署，尚未获得美国FDA授权。Vitestro正在积极推进其在美国的监管审批进程，同时扩大全球临床合作，以支持未来自主诊断性采血技术在全球范围内的商业化。

Photo:

照片：

https://mma.prnewswire.com/media/2927933/Vitestro.jpg

https://mma.prnewswire.com/media/2927933/Vitestro.jpg

SOURCE Vitestro

来源：Vitestro

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示